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Summary
Decision-makers increasingly require comprehensive economic metrics summarising 
and comparing the benefits and costs of controlling zoonotic diseases. The impact 
of disease in people is conventionally quantified in non-monetary terms, usually a 
disability-adjusted life year (DALY), whereas the losses due to disease in animals, 
particularly livestock, are quantified in monetary terms. The potential for the 
development of a non-monetary metric for ill health in animals, based on life years 
lost and disability, is discussed and rejected. Within and across animal species and 
livestock production systems, maximising life spans is not a consistent goal and 
morbidity/disabilities have very different weights and often lead to culling. By relating 
livestock losses to a measure of national income forgone, the recently developed 
alternative of converting monetary losses due to livestock illness into an animal 
loss equivalent (ALE) provides a viable solution. Based on this, the literature on the 
economics of controlling zoonoses is revisited and four options for quantifying and 
comparing benefits and costs are examined and illustrated using numerical examples. 
These are i) the simplistic grouping of all monetary elements and their comparison to 
DALYs averted (described as the aggregate net cost method), ii) the separable costs 
method, iii) the use of ALEs to convert all benefits to a non-monetary equivalent, termed 
the zoonotic DALY (zDALY), or iv) the use of a full monetary cost-benefit analysis, 
based on converting DALYs to a monetary equivalent. The strengths and weaknesses 
of each are discussed. For effective prioritisation and decision-making, it is vital that 
an analytical approach is widely adopted which yields consistent results and which 
supports the control of zoonoses.
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Background
The quest for data and analysis of the economics of zoonoses 
control is now in its fifth decade: the 45th World Health 
Organization (WHO) Executive Board having passed a 
resolution in 1970 recommending that a group of experts 
meet and discuss the subject and commission some pilot 
studies (1). By this time, health economics was already 
recognised as a sub-discipline of economics (2), cost–benefit 
analysis had been an established notion for long enough to 
merit the writing of a survey article (3) and the difficulties 
of putting a monetary value on human life were being 
discussed (4) while alternative non-monetary approaches 
were being developed (5, 6). The early 1970s also saw the 
development of veterinary or animal health economics, 
partly spurred on by the gathering of experts initiated by 
that same WHO resolution, as described in (7). In 1976 
the International Society for Veterinary Epidemiology and 
Economics held its first meeting (8), marking the formal 
launching of the subject.
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However, these two sub-disciplines were, until recently, 
mostly pursued separately, with individual practitioners 
by and large being relatively unfamiliar with the work 
done by the other group. The rapid growth of the One 
Health movement over the last decade, along with a 
greater awareness of zoonoses in general and of the risks 
posed by potentially pandemic zoonoses in particular, has 
intensified the need for a practical, ‘joined-up’ methodology 
for quantifying the economic impact of zoonotic diseases 
and for evaluating their control from a societal rather than a 
single sector viewpoint (9, 10, 11).
This paper examines the options using examples from 
the neglected zoonotic diseases, which mostly impact on 
poorer communities (12). This cluster of endemic diseases 
is useful for analysing the economics of zoonoses control 
because there are a range of possible interventions, different 
breakdowns of disease impact between the human and 
animal sector and varying levels of disease control being 
implemented in different settings.
The economic impact  
of zoonotic disease
The costs imposed by a disease on society consist of the 
money that needs to be spent treating or preventing it 
plus the effect it has on diseased individuals – which, for a 
zoonosis, will include both humans and animals, as laid out 
in the four boxes at the top of Fig. 1. The objective of new 
disease control initiatives is to reduce one or all of these 
four categories. With the growing interest in One Health 
approaches, papers on endemic zoonotic diseases have 
reported on the costs of disease to both human health and 
animal health sectors at local and global levels (e.g. 13, 14, 
15, 16, 17). A smaller number of papers have also reported 
on the economics of controlling specific diseases (e.g. 18, 
19, 20, 21, 22).
Health-adjusted life year (HALY) measures  
to quantify the impact of disease in people
A range of health-adjusted life year (HALY) measures have 
been developed, of which the two currently most commonly 
used are the quality-adjusted life year (QALY) and the 
disability-adjusted life year (DALY) (23). The differences 
between the DALY and the QALY are explained in the 
context of a zoonotic disease in (13). The DALY measures 
burden of disease, and disease control ‘averts’ DALYs. A 
DALY value of 0 is equivalent to a perfectly healthy life 
year and 1 to death, with values in between representing 
different levels of disability. The DALY has two components: 
years of life lost (YLL – measuring the impact of premature 
death) and years of life lived with disability (YLD – 
measuring time spent living with health problems to which 
a range of disability weights are applied). The DALY has 
been widely adopted, notably by WHO, as an international 
measure of the impact of disease and as a basis for assessing 
the global burden of disease. In the context of One Health, 
the DALY has become the preferred measure for expressing 
the impact of zoonoses on human health. The DALY, in its 
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Fig. 1 
Components of the costs and benefits of controlling a zoonotic disease
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global application also packs a moral punch – it implies 
that across the world a life is a life, no matter whose it is nor 
where that person lives or what they earn.
Expenses on treatment  
and prevention in the human sector
In human health economics, costs are divided into direct 
medical and non-medical costs (the latter including health-
sector overheads and costs that patients necessarily incur, 
such as transport and hired care-giving) and indirect 
costs (patient costs while ill: time off from work, seeking 
treatment, hired household help). The different direct 
and indirect costs may or may not be taken into account 
depending on whether the analysis is from the viewpoint 
of an individual stakeholder or of society as a whole (24).
Animal health losses
Losses due to illness in livestock are valued in terms of their 
monetary impact on livestock output. This is defined as the 
total goods produced whether for home consumption or 
sale (meat, milk, skins, wool, animal traction, manure etc.), 
minus animals purchased or brought in, plus any change 
in herd value (7). A range of time periods, methods and 
scales are used: one-year farm budgets, herd models using 
production parameters such as death and fertility rates 
to calculate output, and analyses of the impact of large-
scale changes in the health status of livestock populations 
on supply, demand and prices (producer and consumer 
surplus estimates). Wider impacts may also need to be 
quantified. The possible impacts on trade include a fall in 
prices and a reduction in the number of market outlets as 
a result of movement controls or import bans. Endemic 
diseases such as trypanosomiasis or tick-borne diseases in 
Africa can restrict the livestock breeds farmed and the type 
of production systems used (25).
Within the livestock sector animals have clear commercial 
values; however, when considering companion animals and 
wildlife, estimation is more complex – involving techniques 
that are also familiar in the human health economics sector, 
such as willingness to pay (26, 27).
Expenditure on treatment  
and prevention in the animal sector
As well as suffering losses as a result of their animals’ illness, 
livestock keepers and the local/national Veterinary Services 
incur expenses as they attempt to mitigate or prevent these 
losses. The trade-off between accepting losses in livestock 
and spending money privately or publicly on improving 
their health has been termed the ‘loss–expenditure’ frontier 
and analysed using the tools of economic theory (28).
The analytical dilemma: 
comparing DALYs and dollars
Thus, the societal cost of zoonotic diseases comprises four 
categories, three of which are easily expressed in monetary 
terms, but arguably the most important one: human 
suffering and premature death, is conventionally expressed 
using a HALY.
Do we need an animal ‘DALY’?
As the One Health movement has gained traction, within 
the human health field some have expressed surprise that 
there is no DALY equivalent for animals, while some in the 
veterinary field have observed what an efficient tool the 
DALY is for prioritising and for attracting funding. Thus, 
it has been suggested that an animal ‘DALY’ – reflecting the 
productivity impacts of diseases on livestock – would be a 
useful tool.
If the DALY model were used, then a mortality (YLL) 
component and a morbidity (YLD) component would need 
to be considered.
The length of animals’ lives is not just determined by a 
desire to maximise life, but by other considerations – 
mostly linked to human behaviour and decision-making. 
These include the following.
– Wildlife generally live longer in captivity, but this may 
not be the optimal life for them.
– For many production animals, a longer life is not what 
the livestock producer wants. Animals are fattened to a 
certain weight and then sent for slaughter. If they do not 
reach that weight in a certain time the livestock keeper loses 
money, either by selling them at a lower weight or having 
to keep and feed them for longer. So, ironically, disease can 
prolong an animal’s life.
– Again, for livestock, life expectancy is not governed by 
the natural lifespan of the species, but by human decision-
making. So, in some societies, a sheep’s life could be 
shortened because the family had a wedding and decided 
to slaughter it to celebrate. Cows in extensive production 
systems in Africa are often kept longer (12 or more years) 
than cows in Europe (5–6 years). Livestock are usually only 
kept till they are quite old in more traditional production 
systems where farmers become quite attached to their 
animals, and, as in Africa, there is a limited supply of 
replacement breeding stock.
– It is only for companion animals (pets) that humans try 
to maximise lifespan. So dogs’ life expectancies range from 
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two years or less in many parts of Africa to about 12 years 
in Europe.
Turning to disability, as Table I illustrates, the outcomes for 
people and animals are very different. Lameness or infertility 
tends to lead to culling in many production animals. The 
presence of diseases such as endemic brucellosis and 
tuberculosis are tolerated by livestock keepers, who are 
often unaware that their animals are infected unless a test-
and-slaughter programme identifies them and marks them 
for removal.
Within species there are huge differences in value. Taking 
the example of dogs, probably the species with the biggest 
range of function and worth to humans, the following apply:
– Dogs can be companion animals, virtually regarded as 
family members.
– Working dogs play an important role in helping humans 
in the pursuit of their livelihoods in many situations.
– The commercial value of dogs varies greatly: from zero, 
for non-pedigree puppies given free to neighbours or 
friends, to amounts as high as US $1.5 million, a sum paid 
for a Tibetan mastiff dog in 2014. In general, in Europe and 
North America, a pedigree puppy costs US $500–3,000. In 
court cases involving injuries or death of pets, judges in the 
United States typically award sums which reflect the cost of 
keeping the animal for the duration of its life, for example 
around US $30,000 for a dog.
– Dogs can be eaten; in the past they were eaten in almost 
all parts of the world and still are in some places.
– Dogs can be considered as vermin that must be destroyed, 
for example feral dogs which pose a risk to cattle or sheep 
or are feared as carriers of disease, especially rabies.
Then, there is the issue of combining different species. The 
DALY relates to our own species and translates a deeply 
held moral conviction about the value of human life. 
For animals this is very different. This is where the idea 
of an animal DALY runs into its biggest problem. Many 
zoonotic diseases and many livestock diseases affect more 
than one species. In the absence of a monetary metric, it 
becomes very difficult to compare the death of a sheep to 
the death of a cow, for example. This would become even 
more impossible if somehow an animal ‘DALY’ were to be 
integrated with a human DALY. Many zoonotic diseases are 
particularly important in wildlife, so how would individuals 
of a critically endangered species, such as the mountain 
gorilla, be ranked in relation to people or other animals? Is 
a cow more or less valuable than a much-loved family pet 
dog? Lastly, where does a (possibly disease-carrying) wild 
rat or mouse fit in?
For these reasons, and the ease of comparisons across 
species and production systems, the standard practice of 
valuing animal health impacts in monetary terms does seem 
to be the most practical and consistent. This allows each 
animal’s life or ill health to be valued in the context of its 
purpose and production system.
What about putting  
a monetary value on human life?
Conversely, if the objective is to have all human and animal 
health benefits valued using a single metric, then it is 
possible to turn to the cost–benefit analysis methodology 
used in health economics. Since Mishan’s (4) original 
discussion, standardised methodologies have evolved (33). 
The basic approaches are as follows.
– Human capital: people’s lives are valued in relation to 
their contribution to society and thus implicitly it is the 
Table I 
Selected disability impacts in people and livestock
Condition or disease Disability weight for humans* How would it be for livestock?
Infertility (result of disease) 0.011 (new)
0.180 (old)
In female cattle, infertility results in culling. In the UK between 6% and 8% of dairy cows are culled 
each year because of infertility (29)
Blindness (various causes)** 0.195 (new)
0.510–0.600 (old)
In livestock, blindness usually results in culling
Leg amputation 0.021–0.164 (new)
0.300 (old)
In livestock, amputation usually results in culling. In the UK about 3% of dairy cows are culled 
annually because of lameness in the leg or foot (29). Some farmers treat and retain lame cows, but 
lame work oxen or bulls are usually culled
Tuberculosis (cases) 0.331 (new)
0.271 (old)
Possibly less disabling in cattle than in humans, as cattle are often retained by extensive livestock 
producers despite being infected, with reductions of 5–10% applying to key productivity parameters 
(30). Carcasses may be totally or partially condemned
 
* Each condition was weighted on a scale ranging from 0 (perfect health) to 1 (death). The ‘old’ disability weights are those from Murray & Lopez (31) and the ‘new’ weights those from the 2010 
Global Burden of Disease study (32)
** Of all the conditions, blindness had the widest range of disability weights
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economic impact, not the wider social impact, of ill health 
and premature death that is measured.
– Observed or revealed preferences: the implied values 
which either society or individuals place on human life are 
estimated on the basis of the financial choices made. For 
example, decision-makers’ investments in safety measures 
to prevent known levels of injury or death would provide a 
guideline, as would purchases of health insurance or judges’ 
awards for injury. The notion of the value of a statistical 
life (VSL) falls within this category and has been applied 
in many instances, but it is often considered to apply more 
to wealthy societies and, by some, as having a tendency to 
produce exaggerated values (34).
– Stated preference: people are canvassed as to their 
willingness to pay to avoid certain health risks or enhance 
certain health outcomes. Discrete choice experiments 
involve a more complex approach where those questioned 
are asked about a selection of options, each of which 
has several attributes (cost, service provider, type of 
intervention). These approaches rely on a robust sampling 
strategy and it has been observed that responses can be 
highly subjective and may vary over time, even for the same 
individual.
In contrast to these more formal approaches with a solid 
theoretical underpinning, a more simplistic approach is 
to use measures of average national income per capita as 
a monetary proxy for the value of a year’s human life. This 
valuation reflects the ‘human capital’ approach, but by using 
an ‘average’ figure, it does not discriminate between high 
earners and low earners, rich and poor, rural and urban, 
young and old. Thus, while not reflecting within-country 
income differences and hence ability and willingness to pay, 
by distinguishing between poor and wealthy countries, the 
use of national income measures does nevertheless depart 
from the DALY ideal.
The animal loss equivalent (ALE) –  
a solution to the conundrum
With the debate about the need for an animal DALY ongoing 
for the best part of a decade, a new approach has now been 
proposed (35). Reflecting on the different values of livestock 
in different societies and production systems, in relation 
to human income, it points out that, in parts of Africa, a 
bovine might be worth US $500, which is nearly half of the 
average per capita annual income. By contrast, in Europe 
or North America, a bovine might be worth US $1,500, 
say a twentieth of an annual income of US $30,000. Using 
these fundamental differences as a basis, the adoption of a 
non-monetary ‘animal loss equivalent’ (ALE) is suggested. 
This would be calculated by quantifying livestock losses, 
as usually done in animal health economics, by estimating 
their monetary value as accurately as possible. This figure 
would then be divided by the value of national income to 
produce an ALE. This would reflect both the contribution 
of livestock to the human economy and, more immediately, 
how much time an average income earner would have to 
work in order to obtain the funds to replace that animal. 
This could also be seen as ‘labour time lost’ due to animal 
ill health. Thus, a dead bovine in Africa would be worth 
0.5 ALEs and in Europe or North America, 0.05 ALEs.
When evaluating the losses due to a zoonosis, these ALEs 
could then be added to the conventionally calculated DALYs 
from human health impacts to produce a combined metric, 
the zoonotic DALY, or zDALY.
Analysing the economics 
of interventions to control 
zoonoses
Figure 1 sets out how the costs of disease provide the basis 
for estimating the impact of a particular disease control 
intervention in terms of reductions in some or all of the four 
categories. Adding up all of these benefits, from both the 
human and animal health sectors, yields the total societal 
benefit from controlling the disease using that intervention 
(36). These benefits are then compared to the costs, which 
for a zoonotic disease often depend on interventions 
being implemented jointly by the human sector and the 
veterinary sector; for example, in the case of rabies, the 
former provides post-exposure prophylaxis for people and 
the latter vaccinates dogs.
Basic conventions in human  
and animal health economics
In human health economics the three main approaches used 
for assessing interventions are cost–benefit analysis (CBA), 
cost-effectiveness analysis (CEA) and cost–utility analysis 
(CUA) (24). CBA compares costs to monetary benefits and 
CEA compares costs to a measure of effectiveness – which 
can range from number of patients successfully treated 
through to lives saved. Increasingly, CEA refers to the cost 
of an intervention per DALY averted, whereas CUA refers to 
the cost per unit of utility, a measure of welfare as defined 
in economy theory, and thus usually per QALY gained. In 
the international field and in zoonoses control, the most 
frequently cited measure is a cost-effectiveness ratio (CER) 
based on cost per DALY averted. In all cases, costs are the 
numerator, so that strategies yielding smaller results (lower 
cost–benefit, cost-effectiveness or cost–utility ratios) are to 
be preferred.
When comparing benefits and costs, in human health the 
convention is to analyse the costs and impacts of a range of 
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interventions to tackle a particular health problem. In each 
case, the extra benefits from an additional intervention are 
compared to the extra costs, thus yielding an incremental 
cost-effectiveness ratio (ICER). At an international level, 
until recently, interventions costing less than US $25 per 
DALY were regarded as highly attractive and US $25–
150 as attractive (37). Current WHO cost-effectiveness 
thresholds define interventions costing less than one year’s 
gross domestic product (GDP) per person as being very 
cost-effective, those costing between one and three years’ 
GDP per person as cost-effective, and those costing more 
than three years’ GDP per person as not cost-effective (38). 
A graph illustrating a wide range of CERs for different 
conditions can be found in (39) and the practicalities of 
applying the new thresholds are discussed in (40).
Animal health economics also uses CBA. Relating costs 
to measures of effectiveness, such as a reduction in 
disease prevalence or the number of animals vaccinated, 
is less standard, although it has been recommended that 
veterinary economics make more use of CEA (41). Both at 
the farm level and at the veterinary service level, break-even 
analysis fulfils a useful role when outcomes are uncertain, 
as it indicates what minimum level of benefit or return is 
required to cover costs.
In animal health economics, the basic outline for identifying 
costs and benefits is the ‘partial analysis’ framework. Costs 
are divided into the ‘extra costs’ (of the intervention and 
any extra inputs required for a healthier or more numerous 
livestock population) plus any ‘revenue forgone’ (such as 
negative side-effects of the intervention). Benefits consist of 
‘extra revenue’ (reflecting a reduction in disease losses) and 
‘costs saved’. This framework is most commonly applied at 
a farm level, but provides a basis for identifying benefits 
and costs of interventions on any scale. The emphasis on 
extra revenue/extra costs and revenue forgone/costs saved 
identifies it as an incremental calculation analogous to the 
ICER, in which the benefit unit is monetary rather than a 
measure of effectiveness.
These differences in analytical focus and method are a clear 
reflection of the ways in which the human and animal 
health sectors operate. Human health and the control of 
disease in people is overwhelmingly considered a public 
good, both for communicable and non-communicable 
diseases, with the possible exception of more personal, 
elective interventions such as cosmetic surgery or prolonged 
fertility treatments. In animal health, the control of highly 
contagious and transboundary diseases and zoonoses is 
considered a public good, whereas endemic diseases which 
affect animal productivity and farmers’ incomes – for 
example, mastitis or non-zoonotic worm infestations – is 
the responsibility of livestock keepers (7). Thus, much of 
animal health economics focuses on farm-level decision-
making and on financial benefits. In human health, the 
focus is on spending public-sector funds in such a way as to 
achieve maximum health impact, so a wide range of options 
is costed out and their effects compared.
Four options for zoonoses
To assess the economics of interventions to control zoonotic 
diseases, the impacts on the human and animal health 
sectors need to be integrated so that decision-makers in both 
sectors can assess and interpret outcomes in a way which is 
meaningful both to their sector and to society. Four options 
are investigated here, taking three neglected zoonoses as 
examples: one at national, one at county and one at city 
level (Table II). The first, brucellosis in Mongolia (18), has 
been widely used as a template for economic analyses of 
zoonoses control using the separable costs method (36, 42). 
The second is echinococcosis (19) in Shiqu County, Sichuan, 
in the People’s Republic of China. In these examples, 
monetary benefits from improved livestock productivity 
are substantial, in contrast to the third example, rabies in 
Colombo, Sri Lanka (21), an instance where no livestock 
benefits were quantified. The intervention consisted of 
increased investments in activities which were already 
ongoing, so the additional investments are considered as 
incremental costs, but the previous investments are not 
categorised as costs saved or reduced expenses. Thus, the 
only benefit category represented is DALYs averted.
Throughout, prices are in current US$, applicable at the 
time the study was undertaken, so as to retain the original 
ratios between the animal losses, disease control costs and 
GDP.
Aggregate net cost per DALY averted
The simplest and most obvious way to compare benefits and 
costs would be to combine all the monetary components 
(intervention costs, reductions in health expenditure and 
livestock losses) and compare them to the single non-
monetary unit, the reduced burden of human disease 
expressed in DALYs averted. In order to obtain a net cost 
(NC) per DALY averted, the benefits are subtracted from the 
costs, and divided by the DALYs.
Using the convention of human health economics, this 
method does provide a series of costs per DALY averted, 
which can be ranked, with rabies control being the 
most expensive, and brucellosis the least. However, 
disconcertingly, for all the examples except rabies, the cost 
per DALY averted is negative. This is because the substantial 
monetary benefits from costs saved and from the livestock 
sector outweigh the costs before even considering the 
reduction in the human health burden of the disease.
For exclusively human health sector interventions, the 
implicit approach is often this type of net cost, since the 
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Table II 
Four methods for analysing the benefits and costs of controlling zoonotic diseases illustrated for three contrasting interventions
For an explanation of the formula abbreviations, see Figure 1
Formula
Brucellosis control 
at national level
Echinococcosis control 
at county level
Rabies control 
at city level
Baseline parameters
Location Mongolia Shiqu County, Sichuan, 
People’s Republic of China
Colombo,
Sri Lanka
Source Roth et al., 2003 (18) Budke et al., 2005 (19) Häsler et al., 2014 (21)
Year to which prices apply 2001 2002 2011
GDP (per capita, current US$, year above) 410 238 2,860
Intervention Vaccinate yaks, cattle, 
sheep and goats
Deworm dogs, vaccinate 
sheep and goats* 
Better care for people bitten: 
post-exposure prophylaxis, dog 
bite follow-up; increased dog 
vaccination coverage
Total cost (US$ ‘000) CI 8,300.0 56.5 1,033.9 
% in animal intervention 100.0 100.0 79.2 
Project benefits 
DALYs averted (‘000) RBH 49.0 0.53 0.74
Reduced human health expenditure (US$ ‘000) REH 11,200.0 14.8 –
Reduced animal health losses and expenditure 
(US$ ‘000)
RLA + REA 15,400.0 141.3 –
Aggregate net cost calculation   
Net cost (NC) (US$ ‘000) NC = CI – REH – RLA – REA –18,300.0 –99.7 1,033.9 
Net cost/DALY NC / DALY –373.3 –188.8 1,401.0 
Separable costs parameters   
Monetary benefits (MB) (US$ ‘000) MB = REH + RLA + REA 26,600.0 156.1 0.0
Monetary benefit–cost ratio MB / CI 3.2 2.8 0.0
% monetary benefits HH 100 × REH / MB 42.1 9.5 100.0
% monetary benefits AH 100 × (RLA + REA) /MB 57.9 90.5 0.0
Cost share HH sector (US$ ‘000) % HH x CI /100 3,494.7 5.4 1,033.9
CER (US$) Cost share HH / DALY 71.3 10.2 1,401.0
Cost–benefit analysis parameters   
DALYs as $ (US$ ‘000) DALY × GDP 20,101.1 125.7 2,110.7
Total benefits (TB) (US$ ‘000) TB = (DALY × GDP) + REH + 
RLA + REA
46,701.1 281.8 2,110.7
% benefits HH 100 × (DALY × GDP + REH) / TB 67.0 49.9 100.0
% benefits AH 100 × (RLA + REA) / TB 33.0 50.1 0.0
Benefit–cost ratio TB / CI 5.6 5.0 2.0
Net benefit TB – CI 38,401.1 225.3 1,076.8
zDALY parameters   
DALYs averted (‘000) 49.0 0.53 0.74
Animal loss equivalents (ALE) averted (‘000) ALE = (RLA + REA) / GDP 37.6 0.6 0.0
Health expenditure equivalents (HLE) averted 
(‘000) 
HLE = REH / GDP 27.3 0.1 0.0
zDALY (‘000) DALY + ALE + HLE 113.9 1.2 0.74
% benefits HH 100 × (DALY + HLE) / zDALY 67.0 49.9 100.0
% benefits AH 100 × ALE / zDALY 33.0 50.1 0.0
CER (US$) CI / zDALY 72.9 47.7 1,401.0
% of per capita GDP 100 × (CI/zDALY) / GDP 17.8 20.0 49.0
 
*The authors analysed several scenarios, the one illustrated here is based on the assumption that E. multilocularis has a five-month lifespan
AH: animal health; CER: cost-effectiveness ratio; CI: cost of the intervention; DALY: disability-adjusted life year; GDP: gross domestic product; HH: human health; NC: net cost; zDALY: zoonotic 
disability-adjusted life year
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overall increase in expenditure is compared to the additional 
DALYs averted.
Separable costs method
The separable costs method aims to apportion costs for 
controlling the disease in proportion to the monetary 
benefits obtained from its control. This type of cost 
allocation is the classic approach used for interventions 
involving several sectors (43). Although it is usually applied 
to fully monetised calculations of benefits and costs, it has 
been adapted for zoonoses control (18).
Having quantified all the component elements, the first 
step is to work out the share of monetary benefits accruing 
to the human health sector and the share accruing to the 
animal health sector. Next, these percentages are applied 
to the costs, to derive the share of costs which should be 
attributed to each sector, where CS stands for ‘cost share’. 
The cost-effectiveness ratio (CER) for human health is then 
calculated as its share of costs divided by the DALYs averted. 
For the animal sector the monetary benefits are divided by 
the sector’s share of costs. This yields a benefit–cost ratio 
(BCR) which is identical to that which would be obtained 
for the human sector if the expenditure saved were divided 
by its cost share, so without considering the DALYs. For the 
examples given, it gives a CER which ranges from US $10–
1,400 per DALY averted, well within current thresholds of 
good value for money for each example. These are credible 
figures which make good sense to health service providers. 
This method has been widely adopted for zoonoses 
control interventions (18, 19, 20). By emphasising that a 
substantial share of monetary benefits accrues to the human 
health sector in terms of savings in treating people, it seeks 
to promote greater human health sector funding for disease 
control, even when the control (vaccinating reservoir 
animals as for rabies or brucellosis) is mainly undertaken 
by the animal health sector.
As the rabies example demonstrates, if there are no monetary 
benefits to either sector from the intervention, but DALYs 
are averted, all costs are attributed to the human health 
sector, so the result will be the same as for the aggregate net 
cost method.
Cost–benefit analysis
As discussed above, within human health economics, a 
monetary CBA is sometimes undertaken, using various 
methods to value human life and suffering. In Table II, this 
is done by valuing a DALY at a year’s per capita GDP. Thus, 
RBH is expressed in monetary terms as GDP × DALYs and a 
BCR calculated.
A net benefit (sum of benefits less sum of costs) can also 
be calculated. For a multi-year project, where figures are 
discounted to their present value, this would be in the form 
of a net present value (NPV), and an internal rate of return 
(IRR) could usually also be calculated.
Two things are noticeable from this fully monetised 
analysis. First, including the value of the human health 
benefits in the BCRs makes these much larger than they 
were before: increasing from 3.2 to 5.6 for brucellosis and 
from 2.8 to 5.0 for echinococcosis. Second, their inclusion 
increases the share of benefits attributed to human health, 
from 42% to 67% for brucellosis and from 10% to 50% for 
echinococcosis. For the rabies example, which consists of 
increasing investment in both sectors, the only measured 
benefit is in DALYs, so only a fully monetised CBA allows 
for a BCR to be calculated, yielding a value of 2.0.
zDALY analysis: incorporating the ALE
Lastly, the ALE, as a non-monetary metric representing the 
cost of animal disease to society using a measure of national 
income as a numeraire, allows for the CBA process above 
to be undertaken in reverse, by converting monetary units 
into non-monetary units.
Thus, all monetary benefits are converted to income 
equivalents by dividing their monetary amount by the 
monetary value of one year’s per capita GDP. For livestock 
losses, this yields an ALE. For human health monetary costs 
saved, a similar process yields a human expenditure loss 
equivalent or HLE.
Looking at Table II, this yields CERs with higher costs than 
the separable costs method (up from US $71 to US $73 
for brucellosis, from US $10 to US $48 for echinococcosis, 
with the rabies figure staying constant at US $1,401, as no 
animal benefits were quantified). The difference increases 
as the share of human benefits increases (a function of 
including the DALYs averted in the equation). As the same 
value of one year’s GDP was used in this calculation as 
for the BCR calculation, the shares of each sector in total 
benefits are identical for these two approaches, but as 
noted above, higher for human health than when using the 
separable costs method. The CERs produced can be ranked 
and, as shown in the last line of the table, expressed as a 
proportion of one year’s per capita GDP, ranging from 18% 
to 49% for the examples given, thus falling well within 
WHO’s threshold of very cost-effective interventions.
Each of these four methods has its strengths and weaknesses, 
which are set out in Table III.
Discussion
In this paper the focus has been on trying to find practical 
metrics that can be applied and understood by both the 
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Table III 
Comparison between methods for analysing benefits and costs of zoonotic disease control interventions
Method Strengths Weaknesses Conclusion
Aggregate net cost Maintains the separation of monetary and  
non-monetary components of benefits and costs.
By pooling all monetary elements, provides a 
single consistent net monetary cost figure which 
can be compared to the number of DALYs averted.
Difficult to interpret because it becomes 
negative if there are substantial monetary 
benefits, usually from within the animal sector.
Such negative ‘costs per DALY averted’ give 
the impression that controlling the disease can 
almost be done for free.
Where animal sector benefits are high it could 
lead to disease control being considered 
exclusively or mainly a veterinary responsibility.
Best suited to situations where there 
are low monetary animal benefits so 
that there is a positive net cost per 
DALY.
Separable costs Provides a consistent result without the need to 
try to convert monetary into non-monetary costs 
or vice versa.
Provides a credible cost per DALY figure.
Focuses attention on all four components of 
societal costs.
Highlights the distribution of benefits and costs 
between the two sectors.
Where the control measure is implemented 
largely through the animal sector, emphasises that 
there is a gain to human health and that funding 
from the human/public health sector should be 
allocated to that control measure.
Because the proportion of total costs allocated 
to the health sector is reduced where there are 
monetary benefits from the animal health sector, 
the cost/DALY averted cannot be compared 
to the cost/DALY averted from non-zoonotic 
interventions. Effectively, the DALYs are not 
included in the cost-allocation equation. Thus, it 
is questionable whether the standards of ‘good 
value for money’ (either in monetary or GDP 
terms) can be applied.
Suffers from the classic BCR dilemma: if some 
costs are netted out from the benefits the CER 
will be altered.
Has been widely adopted and is well 
understood by the health sector, 
though less by the animal health 
sector.
In practice, has not often led to 
costs being allocated to each sector 
in proportion to expected monetary 
benefits. Public sector budgets are 
usually allocated to each sector in 
proportion to their actual responsibility 
for achieving control. The challenge is 
to allocate sufficient total funding for 
controlling these diseases.
Cost–benefit 
analysis
Provides a single metric by expressing all figures in 
monetary terms.
Results (NPV, BCR and IRR) are well accepted and 
widely understood by decision-makers.
Provides an equitable analysis of how benefits are 
distributed between the human and animal health 
sectors.
By allowing for a net benefit or NPV to be 
calculated, can avoid the classic BCR dilemma.
Departs from the DALY ideal, in assigning 
different monetary values to a DALY in different 
national-level economic contexts. However, 
does not differentiate between poor and rich 
individuals within a country or reflect their 
different levels of ‘willingness to pay’.
Does not provide either a CER or ICER so is not 
easily compared to other human health sector 
interventions.
There are decisions to be made about which 
value of national income per capita to use to 
best represent a DALY
Suitable for decision-makers preferring 
to evaluate benefits in terms of 
monetary amounts.
Best used alongside the zDALY method 
as these are both consistent and 
complement each other by providing 
both a DALY-based and a fully 
monetised analysis.
zDALY analysis Provides a single metric by expressing all figures in 
zDALY terms.
Results (CER/ICER) are well accepted and widely 
understood by decision-makers and can be ranked 
in relation to currently accepted thresholds of good 
value for money.
Provides an equitable analysis of how benefits are 
distributed between the human and animal health 
sectors.
There are decisions to be made about which 
value and what proportion of national income 
per capita best represent an ALE.
Does not provide a full NPV/BCR or IRR so 
not easily compared to other animal health 
interventions.
Suffers from the classic BCR dilemma: if some 
costs are netted out from the benefits, the CER 
will be altered.
Suitable for decision-makers preferring 
to evaluate benefits in terms of DALYs.
Best used alongside the CBA method, 
as these are both consistent and 
complement each other by providing 
both a DALY-based and a fully 
monetised analysis.
 
ALE: animal loss equivalent; BCR: benefit–cost ratio; CER: cost-effectiveness ratio; DALY: disability-adjusted life year; GDP: gross domestic product; ICER: incremental cost-effectiveness ratio; 
IRR: internal rate of return; NPV: net present value; zDALY: zoonotic disability-adjusted life year
human and animal health sectors, in the context of evaluating 
and ranking interventions to control zoonotic diseases. On 
the veterinary side, the focus has been on animal disease 
losses that are conventionally quantified in monetary terms. 
Thus, the implications of valuing companion animals and 
wildlife (26, 27) and the wider ecosystem impacts which 
underlie a more holistic One Health vision (44) have not 
been brought into this analysis (for more information on 
156 Rev. Sci. Tech. Off. Int. Epiz., 36 (1)
the economics of ecosystems and biodiversity, visit www.
teebweb.org).
The economic analysis of zoonoses control brings out a 
number of classic discussion points. In human health, 
discount rates of 3%–5% are typically used as against rates 
of 6%–12% in animal health. While recent low interest rates 
have encouraged the use of lower discount rates, a disparity 
between human and animal health sector rates remains.
How costs and benefits are defined can affect BCRs. In 
animal health, comparing project costs to net benefits to 
livestock keepers will yield a higher BCR than comparing 
gross benefits to the total costs incurred by both livestock 
keepers and the project. Since CERs are a ratio, they are 
susceptible to the same problem. The calculation of 
incremental costs and their comparison to incremental 
DALYs avoids this problem, but including animal benefits 
may tend to reintroduce it.
The choice of which value of national income to use as a 
numeraire needs more thought and discussion. With respect 
to value, the calculations here have used the Atlas valuation 
of GDP at current, nominal US$, rather than the producer-
price parity (PPP) valuation at international US$. The Atlas 
and PPP valuations are similar for wealthier countries, but 
Atlas is usually much lower than PPP for poorer countries 
(e.g. US $2,860 rather than US $8,949 for Sri Lanka 
in 2011). The Atlas value was used for several reasons. 
All three studies valued costs and monetary benefits at 
current US$. For low-income countries, local salaries, local 
hospitalisation costs and livestock prices would be higher at 
international US$ than at current US$ values, but the prices 
of inputs for disease control would probably be similar 
at international and current US$ values, because many of 
these inputs are sourced internationally. Thus, converting 
to international US$ would alter the BCRs reported in the 
studies. Lastly, taking the lower Atlas US$ GDP valuation 
and thus setting a lower cost-effectiveness threshold, 
effectively requires projects to achieve a higher level of 
economic return. However, a comprehensive economic 
analysis should use international US$, as recommended by 
WHO (38).
The use of GDP also ties in with WHO’s new thresholds 
for value for money which are linked to GDP (38), which 
in turn reflect the suggestion in the Commission on 
Macroeconomics and Health report (45) that a DALY be 
valued at between one and three years’ per capita GDP. A 
comparison of this with the VSL can be found in (46).
Turning to the relation between per capita GDP and a 
DALY, it could be argued that people do not equate their 
time working with their whole available time. If people felt 
that only half their waking time was spent working then 
it could be argued that an ALE, representing the working 
time needed to recoup monetary losses, would only be 
equivalent to half a DALY, which values a person’s whole 
existence. The same logic would then imply that GDP, as 
a reflection of earning power, also only represents half a 
DALY. Thus, the symmetry between the CBA and the 
zDALY approach would be maintained, with the relative 
proportion of benefits attributed to animal and human 
health remaining identical. This is a discussion point for 
further development.
Conclusion
‘If the scientific community was to find an agreement on 
a standardised approach to measure outcomes of rabies 
control in an integrated way, the economic efficiency of 
such control measures could be compared internationally 
and the best approach chosen’ (21).
Accepting the ALE, as a way of converting monetary animal 
benefits into a non-monetary metric, enables animal health 
benefits to be integrated into human health economic 
analyses. This is a much more realistic and viable option 
than trying to develop a DALY-type metric for ill health in 
animals, i.e. a metric based on disability and premature 
death. One great strength of the DALY approach has been 
in evaluating global health burdens, because deaths from 
all causes need to add up to total deaths, although there 
are still unresolved issues around the avoidance of double-
counting for co-morbidities. However, in animal health, 
for many diseases and production systems there is no 
consensus at all on what overall losses are. Disease losses 
are assessed one disease at a time, so that the sum of deaths 
ascribed to various individual causes often greatly exceeds 
the total number of deaths observed. Thus, there remains a 
huge gap to fill in terms of providing more coherent data on 
the impacts of livestock diseases.
Conversely, converting the DALY into monetary terms 
based on GDP does detract from its appeal as a universal 
metric. WHO’s value-for-money criteria implicitly already 
accept this and comparisons are made on a country, not an 
individual, income basis. Similar issues arise when deciding 
whether to apply regional or global life expectancies for 
DALY calculations. Such monetary conversions do not 
diminish the value of being able to calculate and compare 
the burden of disease across countries in terms of DALYs.
To summarise, this paper argues that all four measures 
outlined (aggregate net cost, separable costs, CBA and 
a zoonotic CER based on a non-monetary zDALY metric 
integrating human and animal health benefits) should be 
considered. The latter two are essentially mirror images of 
each other, presenting the same figures: once with monetary 
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benefits and once with non-monetary benefits. In each case, 
the shares of benefits reaped by the animal and human 
sectors are the same. The zDALY-based CER could easily 
be set alongside human-health-only CERs and compared 
across diseases. The CBA yields results which decision-
makers are used to interpreting. Thus, it is recommended 
that these two measures be calculated in a standardised way 
and presented together when assessing the economics of 
interventions to control a zoonotic disease.
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Des DALY, des dollars et des chiens : quelle est la meilleure option 
pour l’analyse économique de la lutte contre les zoonoses ?
A.P.M. Shaw, J. Rushton, F. Roth & P.R. Torgerson
Résumé
Les décideurs politiques sont de plus en plus dépendants de méthodes 
exhaustives de mesure économique permettant de synthétiser et de comparer 
les avantages et les coûts de la lutte contre les zoonoses. Par convention, 
l’impact des maladies humaines est quantifié en des termes non monétaires, à 
savoir, le plus souvent, en « années de vie corrigées de l’incapacité » (DALY), 
tandis que les pertes dues aux maladies animales, en particulier celles affectant 
les animaux d’élevage, sont quantifiées en termes monétaires.  Dans cet article, 
les auteurs envisagent (et réfutent) la possibilité de mettre en œuvre un système 
de mesure non monétaire des problèmes sanitaires chez les animaux qui soit 
basé sur les années de vie perdues ou d’incapacité. La longévité n’est pas un 
objectif uniformément recherché dans tous les systèmes de production, ni pour 
toutes les espèces animales, voire pour tous les individus au sein d’une même 
espèce, et la morbidité et l’incapacité représentent des fardeaux très variables, 
conduisant souvent à l’abattage. Parce qu’elle relie les pertes animales à une 
mesure de la réduction du revenu intérieur entraînée, la récente proposition de 
convertir les pertes monétaires dues aux maladies du bétail en un « équivalent 
pertes animales » (indicateur ALE : animal loss equivalent) constitue une solution 
viable. À partir de ces considérations, les auteurs examinent la littérature dédiée 
aux aspects économiques de la lutte contre les zoonoses en détaillant quatre 
méthodes possibles pour en quantifier et comparer les avantages et les coûts, 
avec des exemples chiffrés. Ces possibilités sont : i) le simple regroupement de 
tous les éléments monétaires et leur comparaison en termes de DALY évitées 
(méthode dite de la présentation agrégée des coûts nets) ; ii) la méthode des 
coûts séparables ; iii) l’utilisation d’un indicateur ALE pour convertir l’ensemble 
des bénéfices en leur équivalent non monétaire, désigné sous le terme de DALY 
zoonotique (zDALY) ; iv) le recours à une analyse monétaire coûts-avantages 
exhaustive, après avoir converti les DALY en leur équivalent monétaire. Les 
auteurs font ressortir les atouts et les faiblesses de chacune de ces méthodes. 
La priorisation et la prise de décisions gagneront en efficacité si les décideurs 
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AVAD, dólares y perros, o cómo analizar idóneamente la economía 
del control de las zoonosis
A.P.M. Shaw, J. Rushton, F. Roth & P.R. Torgerson
Resumen
Cada vez más, las instancias decisorias necesitan parámetros econométricos 
integrales, que sirvan para sintetizar y comparar los costos y beneficios de la 
lucha contra enfermedades zoonóticas. Convencionalmente, los efectos de una 
enfermedad en las personas se cuantifican en términos no monetarios, por lo 
general en forma de «años de vida ajustados en función de la discapacidad» 
(AVAD), mientras que las pérdidas inducidas por las enfermedades en animales, 
en particular el ganado, se cuantifican en valores monetarios. Los autores 
examinan y descartan la posible definición de parámetros no monetarios, 
basados en los años de vida perdidos y en la discapacidad, para cuantificar 
problemas zoosanitarios. Con independencia de la especie animal o el sistema 
de producción ganadera de que se trate, el de lograr una longevidad máxima 
no es un objetivo habitual, y los niveles de morbilidad o discapacidad, que 
suelen desembocar en el sacrificio sanitario, tienen un peso muy variable. En 
fechas recientes ha aparecido una alternativa que, al establecer una relación 
entre las pérdidas de ganado y una medida de la renta nacional prevista, ofrece 
una solución viable: se trata de convertir las pérdidas monetarias causadas por 
enfermedades del ganado en un «equivalente a las pérdidas animales» (animal 
loss equivalent: ALE). Partiendo de esta idea, los autores repasan la bibliografía 
sobre la economía de la lucha contra las zoonosis y examinan cuatro opciones 
para cuantificar y comparar beneficios y costos, ilustrándolas con ejemplos 
numéricos. Se trata de las siguientes: i) el simplificador procedimiento de 
agrupar todos los elementos monetarios y compararlos con los AVAD evitados 
(método que describen como del «costo agregado neto»); ii) el método de los 
costos específicos; iii) el uso de «equivalentes a las pérdidas animales» para 
convertir todos los beneficios en un equivalente no monetario que denominan 
AVAD por zoonosis; y iv) el uso de un análisis monetario completo de la relación 
entre beneficios y costos, basado en la conversión de los AVAD en un equivalente 
monetario. A continuación examinan los puntos fuertes y débiles de cada uno de 
esos métodos, y concluyen que para fijar prioridades y adoptar decisiones con 
eficacia es vital aplicar de forma generalizada un mismo planteamiento analítico, 
que arroje resultados coherentes y ayude así a combatir las zoonosis.
Palabras clave
ALE – Análisis de la relación beneficio-costo – Años de vida ajustados en función de la 
discapacidad – Años de vida ajustados en función de la discapacidad por zoonosis – AVAD 
– AVAD por zoonosis – Control de zoonosis – Costos específicos – Economía – Equivalente 
a las pérdidas animales.
adoptent et appliquent largement une approche analytique permettant d’obtenir 
des résultats cohérents et de renforcer la lutte contre les zoonoses.
Mots-clés
Analyse coûts-avantages – Année de vie ajustée sur l’incapacité – Année de vie ajustée 
sur l’incapacité associée aux zoonoses – Coûts séparés – DALY – DALYz – Économie – 
« Équivalent pertes animales » – Indicateur ALE – Lutte contre les zoonoses.
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